GlobeNewswire

Juniper Networks Wins "Best of Show" Top Awards at Interop Tokyo 2018

Dela

Juniper's MX10008 Universal Chassis and Contrail Enterprise Multicloud Emerge as Grand Prix Winners at Prestigious Awards Ceremony

 

TOKYO, June 14, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that it has captured multiple top honors at Interop Tokyo 2018 for the 12th straight year. The recognition reflects the company's consistent commitment toward delivering innovative and industry-leading networking technology while simplifying the complexities of networking.

Maintaining its award winning-streak at the influential trade show, Juniper triumphed in the following categories this year:

  • "Best of Show" Grand Prix Award (Network Infrastructure): Juniper Networks MX10008 Universal Chassis
  • "Best of Show" Grand Prix Award (Cloud Computing): Contrail Enterprise Multicloud by Juniper Networks
  • "Best of Show" Runners-Up Award (Security): Juniper Networks ATP Appliance
  • "Best of Show" Special Award (Security): Juniper Networks SRX4600 Services Gateway

Continuing Juniper's proud tradition of receiving consecutive "Best of Show" awards at Interop Tokyo since 2007, a prominent judging panel of industry experts and executives selected Juniper's products as award winners from among hundreds of nominations across the industry. Recent Juniper award-winners have included the QFX10008QFX5110 and the MX10003.

As one of the largest network computing trade shows in Asia, Interop Tokyo is renowned for being a top global business technology event, showcasing the very latest in cutting-edge networking products, solutions and services from vendors across the world. This year, Interop Tokyo 2018 attracted more than 140,000 attendees (including co-located events) and featured major keynote addresses and full-fledged conference programs, as well as an associated expo area for showcases by vendors.

Product Highlights:

Juniper Networks MX10008 Universal Chassis

  • The MX10008 completes Juniper's universal chassis portfolio that also includes the PTX and QFX chassis and continues service-scale innovation to usher in the next era of carrier, enterprise and cloud networking.
  • Customers now can have a singular chassis to accommodate a variety of line cards and software for different use-cases, enabling customers to do more with less while simplifying network design and reducing OPEX.
  • In addition, the MX10008 also brings industry-leading and space-saving scale for edge routers at 19.2 Tbps, while also improving per-slot economics for service scale at ~0.6 watts per gigabit.

Contrail Enterprise Multicloud by Juniper Networks

  • Contrail Enterprise Multicloud is the only multicloud-ready orchestration and analytics platform, for any cloud and any workload, across multivendor environments.
  • Integrating both overlay and underlay management into an open platform, Contrail Enterprise Multicloud streamlines workflows and improves end-to-end visibility.
  • Featuring end-to-end policy and control capability, Contrail Enterprise Multicloud enables users to have a single tool for orchestration across overlay and fabric management, bare metal servers, virtual machines, containers and networking devices, private and public clouds and security management.
  • Based on open interfaces and standard protocols, Contrail Enterprise Multicloud can be inserted into diverse networking environments to avoid unnecessary vendor lock-in, all while enabling a clear path toward a secure and automated multicloud.

Juniper Networks Advanced Threat Prevention (ATP) Appliance

  • The ATP Appliance provides comprehensive on-premise protection against a sophisticated ever-changing threat landscape.
  • Utilizing advanced machine learning and behavioral analysis, the ATP Appliance identifies existing and unknown advanced threats in near real-time.
  • With an open API architecture, the ATP Appliance integrates with third-party security devices for seamless, automatic threat mitigation.
  • The ATP Appliance is available in both physical (all-in-one or distributed mode deployment) and virtual (distributed mode only) form factors.

Juniper Networks SRX4600 Services Gateway

  • The high-performance SRX4600 next-generation firewall offers fast, scalable protection across the enterprise private cloud, campus networks, cloud service providers and telcos alike
  • With integrated malware prevention and a full suite of next-generation services, the SRX4600 is optimized to provide consistent and seamless protection across diverse environments
  • As the center point of defense, the SRX4600 offers unprecedented command over your entire security infrastructure, allowing for 'single pane of glass' management through Junos Space Security Director

Supporting Quote

"We are delighted to once again continue Juniper Networks' proud tradition of capturing multiple prestigious awards at Interop Tokyo, across the Network Infrastructure, Cloud Computing and Security categories. It's a major honor to be consecutively recognized every year since 2007 by the esteemed panel, and a strong testament to our commitment of continually challenging the complexities across networking - all while consistently engineering industry-leading products and solutions for our customers."

- Mike Marcellin, SVP and chief marketing officer, Juniper Networks

Additional Resources:

About Juniper Networks
Juniper Networks simplifies the complexities of networking with products, solutions and services in the cloud era to transform the way we connect, work and live. We remove the traditional constraints of networking to enable our customers and partners to deliver automated, scalable and secure networks that connect the world. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on TwitterLinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper and Junos are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

Media Relations:
Juniper Networks
Kenneth Chew
+65 6511 3529
kchew@juniper.net




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Juniper Networks via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum